Nerbio iTOF is the first mobile device managed quantitative monitor of Neuromuscular Blocking Agents (NMBAs) that provides accuracy and ease of use in both surgical anesthesia and COVID-19 mechanical ventilation use.
Nerbio iTOF consists of a rechargeable, Bluetooth connected stimulator device, and a mobile device app that connects to and manages multiple stimulators. This combination allows precise, automated quantitative monitoring of the level of neuromuscular blocking. For Covid-19 patients, wireless control improves caregiver safety while maintaining a high level of patient care.
We are transforming smartphones and tablets into medical devices with high accuracy, reliability, and availability—while allowing easy patient-specific calibration and automation and improving healthcare worker safety. HIPAA compliant AI-assisted data analysis and automated reporting help physicians improve patient care.
The patent-pending Nerbio™ iTOF consists of a nerve stimulation device and a twitch-sensing accelerometer wirelessly connected to a smartphone or tablet. Stimulation data transmit to one or more connected devices that precisely quantizes the stimulation results while providing full control of settings, calibrations, and alerts to manage the anesthetized patient.
Multi-user accessibility and ease of use help eliminate Critical Respiratory Events (CRE) due to residual NMBAs in the post-anesthesia care unit (PACU), and unmonitored patients in the ICU.
Our HIPAA-compliant software platform aggregates all data in a secure, managed cloud service. The Nerbio iTOF backend services include machine learning algorithms that analyze patient data to improve procedural accuracy and optimize device utilization.
Software as a Service (SaaS) extends functionality with easy-to-use tools providing user administration, data logging, reporting, AI-assisted data mining, and automatic software updates.
Nerbio iTOF customers include hospitals, private surgical clinics, insurance providers, and individual physicians.
Nerbio iTOF clinical tests are currently underway at the Keck School of Medicine at USC and in Chile at the Hospital San Borja Arriaran and Hospital Clinico Universidad de Chile, with COVID-19 patients to reduce exposure of healthcare workers and improve patient care.